pioglitazone + topiramate

Pioglitazone + topiramate is a combination drug therapy that pairs pioglitazone, an antihyperglycemic agent used primarily to improve insulin sensitivity in type 2 diabetes mellitus, with topiramate, an anticonvulsant known to promote weight loss and satiety. This combined therapy has been explored for the management of severe metabolic dysfunction associated steatotic liver disease (MASLD), particularly in adolescents with significant liver fibrosis. Pioglitazone acts as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist improving insulin sensitivity and liver histology, while topiramate contributes by reducing body weight and enhancing satiety. The combination aims to leverage the benefits of both drugs—improving metabolic parameters and mitigating side effects such as weight gain seen with pioglitazone alone. Early clinical observations suggest improvements in liver enzymes and fibrosis markers without significant adverse changes in body composition or glycemic control[1][3].

Other names

pioglitazone + topiramate